Changing the remodeling process in heart failure: Basic mechanisms and laboratory results

Current Opinion in Cardiology

Volumn 13, Issue 3, 1998, Pages 156-161

  Francis, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLLAGEN;

CARDIOMYOPATHY; CELL SHAPE; DISEASE COURSE; HEART FAILURE; HEART MUSCLE; HEART MUSCLE INJURY; HEART VENTRICLE REMODELING; HUMAN; HUMAN CELL; MUSCLE CELL; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0031778270     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Packer M: How should physicians view heart failure? The philosophical and physiologic evolution of three conceptual models of the disease. Am J Cardiol 1993, 71:C3-C11.
2. Packer M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248-254.
3. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
4. Francis GS, Cohn JN: Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J 1990, 4:3068-3075.
5. Francis GS, McDonald KM: Left ventricular hypertrophy: an initial response to myocardial injury. Am J Cardiol 1992, 69:3G-9G.
6. Francis GS, McDonald KM, Cohn JN: Neurohumoral activation in preclinical heart failure: remodeling and the potential for intervention. Circulation 1993, 87(suppl IV):IV-90-IV-96.
7. Francis GS, Chu C: Post-infarction myocardial remodelling: why does it happen? Eur Heart J 1995, 16:31-36.
8. Gaudron P, Eilles C, Kugler I, Ertl G: Progressive left ventricular dysfunction and remodeling after myocardial infarction: potential mechanisms and early predictors. Circulation 1993, 87:755-763.
9. Cohn JN: Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995, 91:2504-2507.
10. Anversa P, Loud AV, Levicky V, Guideri G: Left ventricular failure induced by myocardial infarction: II. tissue morphometry. Am J Physiol 1985, 248:H883-H889.
11. Morgan HE, Baker KM: Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation 1991, 83:13-25.
12. Olivetti G, Capasso JM, Meggs LG, Sonnenblick EH, Anversa P: Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 1991, 68:856-869.
13. Francis GS, Carlyle WC: Hypothetical pathways of cardiac myocyte hypertrophy: response to myocardial injury. Eur Heart J 1993, 14:49-56.
14. Lorell BH: Transition from hypertrophy to failure. Circulation 1997, 96:3825-3827.
15. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P: Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994, 89:151-163.
16. Weber KT: Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997, 96:4065-4082. This is an outstanding review of the interstitial matrix remodeling in heart failure.
17. Schneider MD, Roberts R, Parker TG: Modulation of cardiac genes by mechanical stress: the oncogene signalling hypothesis. Mol Biol Med 1991, 8:167-183.
18. Komuro I, Kaida T, Shibazaki Y, Kurabayashi M, Katoh Y, Ho E, Takaku F, Yazaki Y: Stretching cardiac myocytes stimulates protooncogene expression. J Biol Chem 1989, 265:3595-3698.
19. Sadoshima J, Xu Y, Slayter HS, Ixumo S: Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993, 75:977-984.
20. Yazaki Y, Komuro I, Yamazaki T, Tobe K Maemura K, Kadowaki T, Nagai R: Role of protein kinase system in the signal transduction of stretchmedicated protooncogene expressions and hypertrophy of cardiac myocytes. Mol Cell Biochem 1993, 119:11-16.
21. Watson PA: Mechanical activation of signaling pathways in the cardiovascular system. Trends Cardiovasc Med 1996, 6:73-79.
22. Komuro I, Yazaki Y: Intracellular signaling pathways in cardiac myocytes induced by mechanical stress. Trends Cardiovasc Med 1994, 4:117-121.
23. Force T, Pombo CM, Avruch JA, Bonventre JV, Kyriakis JM: Stress-activated protein kinases in cardiovascular disease. Circ Res 1996, 78:947-953.
24. Drexler H, Hasenfuss G, Holubarsch C: Signaling pathways in failing human heart muscle cells. Trends Cardiovasc Med 1997, 7:151-160.
25. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236-241.
26. Torre-Amione G, Kapadia S, Lee J, Durand J, Bies RD, Young JB, Mann DL: Tumor necrosis factor-a and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704-711. An important clinical study provides evidence that tumor necrosis factor-α is operative in human heart failure.
27. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL: Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997, 95:1247-1252. This report links tumor necrosis factor-α to myocyte hypertrophy.
28. Kunisada K, Hirota H, Fujio Y, Matsui H, Tani Y, Yamauchi-Takihara K, Kishimoto T: Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation 1996, 94:2626-2632.
29. Hirota H, Yoshida K, Taga T, Kishimoto T: gp130 signaling pathways: recent advances and implications for cardiovascular disease. Trends Cardiovasc Med 1996, 6:109-115.
30. Katz AM: Cardiomyopathy of overload: a major determinant of prognosis in congestive heart failure. N Engl J Med 1990, 322:100-110.
31. Chien KR, Zhu H, Knowlton KU, Miller-Hance W, van-Blisen M, O'Brien TX, Evans SM: Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 1993, 55:77-95.
32. Hinton RB, Hebbar L, Cox MH, Mukherjee R, Joshi JD, Crawford FA Jr, Spinale FG: Left ventricular regional myocyte contractility in normal and heart failure states. J Mol Cell Cardiol 1997, 29:1939-1946.
33. Melillo G, Lima JAC, Judd RM, Goldschmidt-Clermont PJ, Silverman HS: Intrinsic myocyte dysfunction and tyrosine kinase pathway activation underlie the impaired wall thickening of adjacent regions during postinfarct left ventricular remodeling. Circulation 1996, 93:1447-1458. An important study in rats with myocardial infarction indicates that isolated myocytes adjacent of the infarct are dysfunctional.
34. Anand IS, Liu D, Chugh SS, Prahas AJC, Gupta S, John R, Popescu F, Chandrashekhar Y: Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Circulation 1997, 96:3974-3984. A critically important study implies that isolated myocyte function is normal during the development of left ventricular modeling.
35. Geenen DL, Malhotra A, Scheuer J: Regional variation in rat cardiac myosin isoenzymes and ATPase activity after infarction. Am J Physiol 1989, 256:H745-H750.
36. Dixon IM, Lee SL, Dhalla NS: Nitrendipine binding in congestive heart failure due to myocardial infarction. Circ Res 1990, 66:782-788.
37. Neubauer S, Horn, Naumann A, Tian R, Hu K, Laser M, Friedrich J, Gaudron P, Schnackerz K, Ingwall JS, Ertl G: Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. J Clin Invest 1995, 95:1092-1100.
38. 31P-MRS study. Circulation 1996, 94:1089-1100.
39. Gerdes AM, Kellerman SE, Moore JA, Muffly KE, Clark LC, Reaves PY, Malec KB, McKeown PP, Schocken DD: Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation 1992, 86:426-430.
40. Gerdes AM, Capasso JM: Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol 1995, 27:849-856.
41. Liu Z, Hilbelink DR, Crockett WB, Gerdes AM: Regional changes in hemodynamics and cardiac myocyte size in rats with aortocaval fistulas: developing and established hypertrophy. Circ Res 1991, 69:52-58.
42. Spinale FG, Zellner JL, Tomita M, Crawford FA, Zile MR: Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res 1991, 69:1058-1067.
43. Kajstura J, Zhang X, Liu Y, Szoke E, Cheng W, Olivetti G, Hintze TH, Anversa P: The cellular basis of pacing-induced dilated cardiomyopathy: myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995, 92:2306-2317.
44. Spinale FG, Eble DM, Mukherjee R, Johnson WS, Walker JD: Left ventricular and myocyte structure and function following chronic ventricular tachycardia in rabbits. Basic Res Cardiol 1994, 89:456-467.
45. Spinale FG, Tanaka R, Crawford FA, Zile MR: Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy. Circulation 1992, 85:717-729.
46. Spinale FG, Tempel GE, Mukherjee R, Eble DM, Vacchiano CA, Zile MR: Cellular and molecular alterations in the beta adrenergic system with cardiomyopathy induced by tachycardia. Cardiovasc Res 1994, 28:1243-1250.
47. Tanaka R, Bulbright BM, Mukherjee R, Burchell SA, Crawford FA, Zile MR, Spinale FG: The cellular basis for the blunted response to beta-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy. J Mol Cell Cardiol 1993, 25:1215-1233.
48. Spinale FG, Johnson WS, Wang Y, Wang Z, Mukherjee R, Hebbar L, Jones BU: Direct effects of chronic beta-adrenergic receptor blockade on left ventricular and myocyte function in a model of tachycardia-induced congestive heart failure. J Card Fail 1996, 2:311-318.
49. Spinale FG, Walker JD, Mukherjee R, lannini JP, Keever AT, Gallagher KP: Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits: beneficial effects on left ventricular and myocyte function. Circulation 1997, 95:1918-1929.
50. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Armin-Barker A, Powell JR, Koster WH: Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy: effects on left ventricular and myocyte structure and function. Circulation 1995, 92:562-578.
51. Spinale FG, Crawford FA Jr, Hewett KW, Carabello BA: Ventricular failure and cellular remodeling with chronic supraventricular tachycardia. J Thorac Cardiovasc Surg 1991, 102:874-882.
52. McCune SA, Baker PB, Stills HF Jr.: SHHF/Mcc-cp rat: model of obesity, non-insulin dependent diabetes, and congestive heart failure. ILAR News 1990, 32:23-27.
53. Gerdes AM, Onodera T, Wang X, McCune SA: Myocyte remodeling during the progression to failure in rats with hypertension. Hypertension 1996, 28:609-614. This animal study points out that myocyte elongation is a dominant force in the remodeling process in a paradigm of hypertension and diabetes.
54. Gerdes EM, Kellerman SE, Schocken DP: Implications of cardiomyocyte remodeling in heart dysfunction. In The Failing Heart. Edited by Dhalla NS, Beamish RE, Takeda N, Nagano M. New York: Raven Press; 1995:197-205.
55. Woller RC, Taga T, Saito M, Narazaki M, Kishimoto T, Glembotski CC, Vernallis AB, Heath JK, Pennica D, Wood WI, et al.: Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy: assembly of sarcomeric units in series via gp130/leukemia inhibitory factor receptor-dependent pathways. J Bio Chem 1996, 271:9535-9543.
56. Brooks WW, Bing OHL, Robinsn KG, Slawsky MT, Chaletsky DM, Conrad CH: Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997, 96:4002-4010.
57. Harding SE, Jones SM, del Monte F, Vescovo G, Poole-Wilson PA: Isolated ventricular myocytes from failing and non-failing human heart: the relation of age and clinical status to isoproterenol response. J Mol Cell Cardiol 1992, 24:549-564.
58. del Monte F, Harding SE, Rosano GMC, Poole-Wilson PA: Contractile properties of hypertrophic and non-hypertrophic human ventricular myocytes. J Am Coll Cardiol 1993, 21:778-783.
59. Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE: Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 1995, 92:2540-2549.
60. Beltrami CA, Finato N, Rocco M, Geruglio GA, Puncelli C, Cigola E, Sonnenblick EH, Olivetti G, Anversa P: The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 1995, 27:291-305.
61. Levin HR, Oz MC, Chen JM, Packer M, Rose EA, Burkhoff D: Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation 1995, 91:2717-2720.
62. James KB, McCarthy PM, Thomas JD, Vargo R, Hobbs RE, Sapp S, Bravo E: Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation 1995, 92:11-191-11-195.
63. Müller J, Wallukat G, Wang Y, Dandel M, Spiegelsberger S, Semrau S, Brandes K, Theodoridis V, Loebe M, Meyer R, et al.: Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 1997, 96:542-549. A careful description is provided of reverse remodeling after use of left ventricular assist device, thereby reducing the need for heart transplantation.
64. Eichhorn EJ, Bristow MR: Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996, 94:2285-2296. This is an important review of the emerging role of β-adrenergic blockers for the treatment of heart failure and how they might reduce progression of heart failure by improving the volume and performance of the left ventricle.
65. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the intact human heart: downregulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997, 100:2315-2324. This milestone article describes down-regulation of α-heavy myosin chain (HMC) and up-regulation of β-HMC human failing myocardium, thus providing evidence for a mechanism of diminished myocardial performance in human heart failure.